Literature DB >> 28479207

Measures That Identify Prescription Medication Misuse, Abuse, and Related Events in Clinical Trials: ACTTION Critique and Recommended Considerations.

Shannon M Smith1, Judith K Jones2, Nathaniel P Katz3, Carl L Roland4, Beatrice Setnik5, Jeremiah J Trudeau6, Stephen Wright7, Laurie B Burke8, Sandra D Comer9, Richard C Dart10, Raymond Dionne11, J David Haddox12, Jerome H Jaffe13, Ernest A Kopecky14, Bridget A Martell15, Ivan D Montoya16, Marsha Stanton17, Ajay D Wasan18, Dennis C Turk19, Robert H Dworkin20.   

Abstract

Accurate assessment of inappropriate medication use events (ie, misuse, abuse, and related events) occurring in clinical trials is an important component in evaluating a medication's abuse potential. A meeting was convened to review all instruments measuring such events in clinical trials according to previously published standardized terminology and definitions. Only 2 approaches have been reported that are specifically designed to identify and classify misuse, abuse, and related events occurring in clinical trials, rather than to measure an individual's risk of using a medication inappropriately: the Self-Reported Misuse, Abuse, and Diversion (SR-MAD) instrument and the Misuse, Abuse, and Diversion Drug Event Reporting System (MADDERS). The conceptual basis, strengths, and limitations of these methods are discussed. To our knowledge, MADDERS is the only system available to comprehensively evaluate inappropriate medication use events prospectively to determine the underlying intent. MADDERS can also be applied retrospectively to completed trial data. SR-MAD can be used prospectively; additional development may be required to standardize its implementation and fully appraise the intent of inappropriate use events. Additional research is needed to further demonstrate the validity and utility of MADDERS as well as SR-MAD. PERSPECTIVE: Identifying a medication's abuse potential requires assessing inappropriate medication use events in clinical trials on the basis of a standardized event classification system. The strengths and limitations of the 2 published methods designed to evaluate inappropriate medication use events are reviewed, with recommended considerations for further development and current implementation.
Copyright © 2017 American Pain Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Medication abuse; abuse potential; medication misuse

Mesh:

Substances:

Year:  2017        PMID: 28479207      PMCID: PMC5660635          DOI: 10.1016/j.jpain.2017.03.015

Source DB:  PubMed          Journal:  J Pain        ISSN: 1526-5900            Impact factor:   5.820


  29 in total

Review 1.  Research design considerations for clinical studies of abuse-deterrent opioid analgesics: IMMPACT recommendations.

Authors:  Dennis C Turk; Alec B O'Connor; Robert H Dworkin; Amina Chaudhry; Nathaniel P Katz; Edgar H Adams; John S Brownstein; Sandra D Comer; Richard Dart; Nabarun Dasgupta; Richard A Denisco; Michael Klein; Deborah B Leiderman; Robert Lubran; Bob A Rappaport; James P Zacny; Harry Ahdieh; Laurie B Burke; Penney Cowan; Petra Jacobs; Richard Malamut; John Markman; Edward Michna; Pamela Palmer; Sarah Peirce-Sandner; Jennifer S Potter; Srinivasa N Raja; Christine Rauschkolb; Carl L Roland; Lynn R Webster; Roger D Weiss; Kerry Wolf
Journal:  Pain       Date:  2012-07-05       Impact factor: 6.961

Review 2.  Assessing abuse liability during drug development: changing standards and expectations.

Authors:  K A Schoedel; E M Sellers
Journal:  Clin Pharmacol Ther       Date:  2008-01-23       Impact factor: 6.875

3.  Development and feasibility of the misuse, abuse, and diversion drug event reporting system (MADDERS®).

Authors:  Roi Treister; Jeremiah J Trudeau; Richard Van Inwegen; Judith K Jones; Nathaniel P Katz
Journal:  Am J Addict       Date:  2016-11-04

4.  Aberrant behaviors with prescription opioids and problem drug use history in a community-based cohort of HIV-infected individuals.

Authors:  Luke Hansen; Joanne Penko; David Guzman; David R Bangsberg; Christine Miaskowski; Margot B Kushel
Journal:  J Pain Symptom Manage       Date:  2011-07-30       Impact factor: 3.612

Review 5.  Classification and definition of misuse, abuse, and related events in clinical trials: ACTTION systematic review and recommendations.

Authors:  Shannon M Smith; Richard C Dart; Nathaniel P Katz; Florence Paillard; Edgar H Adams; Sandra D Comer; Aldemar Degroot; Robert R Edwards; David J Haddox; Jerome H Jaffe; Christopher M Jones; Herbert D Kleber; Ernest A Kopecky; John D Markman; Ivan D Montoya; Charles O'Brien; Carl L Roland; Marsha Stanton; Eric C Strain; Gary Vorsanger; Ajay D Wasan; Roger D Weiss; Dennis C Turk; Robert H Dworkin
Journal:  Pain       Date:  2013-06-20       Impact factor: 6.961

6.  Cross validation of the current opioid misuse measure to monitor chronic pain patients on opioid therapy.

Authors:  Stephen F Butler; Simon H Budman; Gilbert J Fanciullo; Robert N Jamison
Journal:  Clin J Pain       Date:  2010 Nov-Dec       Impact factor: 3.442

Review 7.  Principles of laboratory assessment of drug abuse liability and implications for clinical development.

Authors:  Lawrence P Carter; Roland R Griffiths
Journal:  Drug Alcohol Depend       Date:  2009-05-14       Impact factor: 4.492

8.  A new tool to assess and document pain outcomes in chronic pain patients receiving opioid therapy.

Authors:  Steven D Passik; Kenneth L Kirsh; Laurie Whitcomb; Russell K Portenoy; Nathaniel P Katz; Leah Kleinman; Sheri L Dodd; Jeffrey R Schein
Journal:  Clin Ther       Date:  2004-04       Impact factor: 3.393

9.  Prescription Opioid Misuse Index: a brief questionnaire to assess misuse.

Authors:  Janet S Knisely; Martha J Wunsch; Karen L Cropsey; Eleanor D Campbell
Journal:  J Subst Abuse Treat       Date:  2008-07-26

10.  A multicenter, primary care-based, open-label study to identify behaviors related to prescription opioid misuse, abuse, and diversion in opioid-experienced patients with chronic moderate-to-severe pain.

Authors:  Beatrice Setnik; Carl L Roland; Kenneth W Sommerville; Glenn C Pixton; Robert Berke; Anne Calkins; Veeraindar Goli
Journal:  J Pain Res       Date:  2015-07-09       Impact factor: 3.133

View more
  2 in total

Review 1.  Design and conduct of confirmatory chronic pain clinical trials.

Authors:  Nathaniel Katz
Journal:  Pain Rep       Date:  2020-12-18

2.  Research approaches for evaluating opioid sparing in clinical trials of acute and chronic pain treatments: Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials recommendations.

Authors:  Jennifer S Gewandter; Shannon M Smith; Robert H Dworkin; Dennis C Turk; Tong J Gan; Ian Gilron; Sharon Hertz; Nathaniel P Katz; John D Markman; Srinivasa N Raja; Michael C Rowbotham; Brett R Stacey; Eric C Strain; Denham S Ward; John T Farrar; Kurt Kroenke; James P Rathmell; Richard Rauck; Colville Brown; Penney Cowan; Robert R Edwards; James C Eisenach; McKenzie Ferguson; Roy Freeman; Roy Gray; Kathryn Giblin; Hanna Grol-Prokopczyk; Jennifer Haythornthwaite; Robert N Jamison; Marc Martel; Ewan McNicol; Michael L Oshinsky; Friedhelm Sandbrink; Joachim Scholz; Richard Scranton; Lee S Simon; Deborah Steiner; Kenneth Verburg; Ajay D Wasan; Kerry Wentworth
Journal:  Pain       Date:  2021-11-01       Impact factor: 7.926

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.